Bioxyne Limited (AU:BXN) has released an update.
Bioxyne Limited has issued 145 million new shares at $0.01 each, as part of a capital raise announced on April 18, 2024, complying fully with the relevant provisions of the Corporations Act. The company specializes in health and wellness products, including alternative therapeutics and investigational medicines, operating internationally with a significant presence in the UK, Europe, Japan, and Australia.
For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.
